temozolomide has been researched along with pci 32765 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Bao, S; Bian, XW; Chen, C; Chen, Y; Fang, X; Feng, H; Gimple, RC; Guryanova, OA; He, Z; Huang, Z; Jiang, T; Kim, L; Kung, HF; Liu, C; Liu, Q; Ping, YF; Rich, JN; Shi, Y; Wang, W; Wang, X; Wu, J; Wu, Q; Yu, JS; Zhang, W; Zhou, W | 1 |
He, YZ; Li, X; Wang, L | 1 |
Barbieux, S; Bossard, JB; Boyle, EM; Cambier, N; Carpentier, B; Chanteau, G; Escure, G; Hieulle, J; Morschhauser, F; Renaud, L; Terriou, L; Tilmont, R; Wemeau, M | 1 |
3 other study(ies) available for temozolomide and pci 32765
Article | Year |
---|---|
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Cytokine Receptor gp130; Glioma; Janus Kinase 2; Mice; Models, Biological; Neoplastic Stem Cells; Neural Stem Cells; Piperidines; Protein Binding; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Radiation Tolerance; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Survival Analysis; Temozolomide | 2018 |
[Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Piperidines; Positron Emission Tomography Computed Tomography; Temozolomide | 2020 |
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Piperidines; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide | 2021 |